<DOC>
	<DOCNO>NCT01662505</DOCNO>
	<brief_summary>To investigate safety , tolerability , maximum tolerate dose volasertib Japanese patient AML</brief_summary>
	<brief_title>Volasertib Japanese Patients With Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients diagnosis AML ( except acute promyelocytic leukemia , APL ) accord World Health Organization definition one following feature screen Relapsed refractory AML Untreated AML patient consider suitable standard induction therapy accord investigator 's judgement 2 . Male female patient age &gt; /= 18 year time inform consent 3 . Eastern Cooperative Oncology Group performance status score 0 2 screen 4 . Signed write informed consent consistent Japanese Good Clinical Practice . Exclusion criterion : 1 . Patients APL 2 . Patients third later relapse 3 . Prior stem cell transplantation 4 . Treatment systemic therapy primary disease ( include investigational drug ) within 14 day first dose volasertib exception hydroxyurea , lack recovery acute toxicity clinically significant adverse event pertinent prior systemic therapy 5 . Treatment gemtuzumab ozogamicin within 6 week first dose volasertib 6 . Concomitant medication/treatment antileukemic chemotherapy ( systemic intrathecal ) , radiotherapy , immunotherapy , investigational agent receive study treatment 7 . Other malignancy require treatment time screen 8 . Clinical central nervous system ( CNS ) symptom deem investigator related leukemic CNS involvement require treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>